全膝关节置换术与非手术治疗在正常体重、超重、肥胖、重度肥胖、病态肥胖及超级肥胖患者中的成本效益:一项马尔可夫模型研究
本研究采用马尔可夫模型,比较6个BMI队列中全膝关节置换术(TKA)与非手术治疗(NM)在15年内的成本效用。结果显示,不同BMI类别的增量成本效益比(ICER)从非肥胖的3317美元/QALY到超级肥胖的11878美元/QALY不等;在30000美元/QALY阈值下,BMI<50的患者TKA具有成本效益的概率为100%,超级肥胖患者为99.16%。结论认为,尽管超级肥胖患者TKA费用更高,但患者结局的显著改善使其具有成本效益,基于BMI限制TKA会导致不合理的医疗可及性损失。
要点
- 在15年期内,TKA vs NM的ICER在非肥胖组为3317美元/QALY,超重组为2837美元/QALY,肥胖组为2947美元/QALY。
- 重度肥胖组ICER为3536美元/QALY,病态肥胖组为5531美元/QALY,超级肥胖组为11878美元/QALY。
- 在30000美元/QALY阈值下,TKA在BMI<50患者中100%模拟具有成本效益,超级肥胖患者为99.16%。
核心结论
- 尽管对超级肥胖患者行TKA费用更高,但患者结局的显著改善使其具有成本效益。
- 基于BMI限制TKA会导致不合理的医疗可及性损失。
研究设计与样本
- 采用马尔可夫模型,比较TKA与NM在6个BMI组(非肥胖[18.5-24.9]、超重[25-29.9]、肥胖[30-34.9]、重度肥胖[35-39.9]、病态肥胖[40-49.9]和超级肥胖[50+]患者)15年内的成本效用。
- 模型参数(转移概率如翻修、再翻修、死亡,效用和成本)来自文献估计。
- 模型仅纳入直接医疗成本,未纳入间接社会成本;成本和效用按每年3%贴现。
- 主要结局为TKA vs NM的增量成本效益比(ICER)。
- 对模型参数进行单因素和概率敏感性分析以确定模型的稳健性。
主要发现
- 15年期内,TKA vs NM的ICER在不同BMI类别分别为:非肥胖3317美元/QALY、超重2837美元/QALY、肥胖2947美元/QALY、重度肥胖3536美元/QALY、病态肥胖5531美元/QALY、超级肥胖11878美元/QALY。
- 较高BMI组倾向于有更高的增量QALYs和更高的增量成本。
- 以30000美元/QALY为ICER阈值的概率敏感性分析显示,TKA在BMI<50患者中100%的模拟中具有成本效益,在超级肥胖患者中99.16%的模拟中具有成本效益。
关键数值与推荐
- 非肥胖组(BMI 18.5-24.9)TKA vs NM的ICER为3317美元/QALY。
- 超重组(BMI 25-29.9)TKA vs NM的ICER为2837美元/QALY。
- 肥胖组(BMI 30-34.9)TKA vs NM的ICER为2947美元/QALY。
- 重度肥胖组(BMI 35-39.9)TKA vs NM的ICER为3536美元/QALY。
- 病态肥胖组(BMI 40-49.9)TKA vs NM的ICER为5531美元/QALY;超级肥胖组(BMI 50+)TKA vs NM的ICER为11878美元/QALY。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We estimated the cost-effectiveness of performing total knee arthroplasty (TKA) vs nonoperative management (NM) among 6 body mass index (BMI) cohorts. METHODS: A Markov model was used to compare the cost-utility of TKA and NM in 6 BMI groups (nonobese [BMI 18.5-24.9], overweight [25-29.9], obese [30-34.9], severely obese [35-39.9], morbidly obese [40-49.9], and super-obese [50+] patients) over a 15-year period. Model parameters for transition probability (ie, revision, re-revision, death), utility, and costs were estimated from the literature. Direct medical costs but not indirect societal costs were included in the model. Costs and utilities were discounted 3% annually. The primary outcome was the incremental cost-effectiveness ratio (ICER) of TKA vs NM. One-way and probabilistic sensitivity analyses of the model parameters were performed to determine the robustness of the model. RESULTS: Over the 15-year period, the ICERs for the TKA vs NM for the different BMI categories were nonobese ($3317/quality-adjusted life years [QALYs]), overweight ($2837/QALY), obese ($2947/QALY), severely obese ($3536/QALY), morbidly obese ($5531/QALY), and super-obese ($11,878/QALY). The higher BMI groups tended to have higher incremental QALYs and also higher incremental costs. The probabilistic sensitivity analysis with an ICER threshold of $30,000/QALY showed that TKA would be cost-effective in 100% of simulations of patients with a BMI<50 and 99.16% of super-obese simulations. CONCLUSION: While performing TKA on super-obese patients is more expensive, the substantial improvements in patient outcomes make it cost-effective. Therefore, withholding TKA care based on a BMI would lead to an unjustified loss of health-care access.
引用
- Ponnusamy KE, Vasarhelyi EM, Somerville L, et al. Cost-Effectiveness of Total Knee Arthroplasty vs Nonoperative Management in Normal, Overweight, Obese, Severely Obese, Morbidly Obese, and Super-Obese Patients: A Markov Model. J Arthroplasty. 2018. PMID: 29550168. doi:10.1016/j.arth.2018.02.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。